Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01822925 · ClinicalTrials.gov registry record · Phase 2
Study of DA-9801 to Treat Diabetic Neuropathy
A Phase 2 study of Diabetic Neuropathy, sponsored by NeuroBo Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 128
- Enrollment target
- 14
- Study locations
NCT01822925: Completed Phase 2 study of Diabetic Neuropathy, sponsored by NeuroBo Pharmaceuticals.
NCT01822925 is a Phase 2 study of Diabetic Neuropathy that has completed, run by NeuroBo Pharmaceuticals. The registered enrollment target is 128 participants, below the 168-participant average among 8 other Diabetic Neuropathy trials with a reported enrollment target (24% lower). The trial reports 14 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01822925, a Phase 2 study of Diabetic Neuropathy, has completed, sponsored by NeuroBo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 128 participants
- Enrollment target
- 14
- Study locations
Study Summary
To evaluate the effectiveness of DA-9801 at 300mg, 600mg, 900mg and placebo, in reducing pain in subjects with diabetic neuropathic pain compared to their baseline values.
Primary Outcome
Pain score was assessed by the subject using the 11-point Likert rating scale for pain (0=no pain to 10=worst possible pain) prior to conduct of any other study assessment. The change in clinic visit pain score at the 12-week visit was compared to baseline.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG DA-9801 300mg
- DRUG DA-9801 600mg
- DRUG DA-9801 900mg
Study Locations (14)
Texas
- KRK Research - Dallas
- North Texas Endocrine Center - Dallas
- Houston Foot & Ankle Care - Houston
California
- Center for United Research, Inc. - Lakewood
- Diablo Clinical Research - Walnut Creek
Florida
- PAB Clinical Research - Brandon
- Metabolic Research Institute, Inc. - West Palm Beach
Connecticut
- Clinical Research Consulting, LLC - Milford
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Novex Clinical Research, Inc. - New Bedford
New York
- Albany Medical Center - Albany
South Carolina
- Coastal Carolina Research Center - Mt. Pleasant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2013-11 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
What the finished NCT01822925 record still lists
NCT01822925 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, below the 168-participant average among 8 other Diabetic Neuropathy trials with a reported enrollment target (24% lower).
The record links to 1 condition, with Diabetic Neuropathy appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01822925 lists 14 locations in 10 states (Texas, California, Florida).
Frequently Asked Questions
What is clinical trial NCT01822925 about?
NCT01822925 is a clinical study titled "Study of DA-9801 to Treat Diabetic Neuropathy". To evaluate the effectiveness of DA-9801 at 300mg, 600mg, 900mg and placebo, in reducing pain in subjects with diabetic neuropathic pain compared to their baseline values.
What is the current status of trial NCT01822925?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 128 participants. The study started on 2013-11. Estimated completion is 2015-01.
What conditions does trial NCT01822925 study?
This clinical trial studies the following conditions: Diabetic Neuropathy.
What interventions are being tested in trial NCT01822925?
The interventions under investigation include: Placebo (DRUG), DA-9801 300mg (DRUG), DA-9801 600mg (DRUG), DA-9801 900mg (DRUG).
Who is sponsoring clinical trial NCT01822925?
This trial is sponsored by NeuroBo Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01822925 being conducted?
This trial has 14 study locations across California, Connecticut, Florida, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01822925's enrollment target sits among peer trials
128 5th of 8 higher than 4 of 8 other Diabetic Neuropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Neuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy
COMPLETED · Phase 2
-
The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy
COMPLETED · Phase 2
-
The Effect of Ruboxistaurin on Small Fiber Function
COMPLETED · Phase 2
-
Clinical Outcomes Related to Treatment of Distal Symmetric Polyneuropathy Using Semiconductor Embedded Therapeutic Socks
RECRUITING · NA
-
Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project
ACTIVE NOT RECRUITING
-
Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia